Free Trial

Extendicare (TSE:EXE) Stock Price Passes Below Two Hundred Day Moving Average - Here's What Happened

Extendicare logo with Medical background

Key Points

  • Extendicare Inc. shares fell below their 200-day moving average to C$12.33, with the last traded price at C$12.39.
  • Analysts have set a consensus target price of C$13.98 with ratings ranging from "hold" to "strong buy" for the stock.
  • The company recently announced a dividend of $0.042 per share, resulting in a yield of 3.81%, payable on August 15th to shareholders of record after July 31st.
  • Looking to export and analyze Extendicare data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Extendicare Inc. (TSE:EXE - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of C$12.90 and traded as low as C$12.33. Extendicare shares last traded at C$12.39, with a volume of 167,731 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. National Bank Financial raised Extendicare to a "strong-buy" rating in a research report on Wednesday, July 16th. TD Securities raised their price target on Extendicare from C$13.00 to C$15.00 and gave the company a "hold" rating in a report on Thursday, May 22nd. National Bankshares set a C$15.40 price objective on Extendicare and gave the stock an "outperform" rating in a report on Thursday, July 17th. Finally, BMO Capital Markets boosted their price target on Extendicare from C$13.50 to C$14.50 in a report on Monday, May 12th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of C$13.98.

Get Our Latest Analysis on Extendicare

Extendicare Trading Down 1.6%

The company has a debt-to-equity ratio of 283.02, a quick ratio of 0.98 and a current ratio of 0.62. The business has a fifty day simple moving average of C$13.69 and a 200 day simple moving average of C$12.91. The company has a market cap of C$1.01 billion, a P/E ratio of 15.47 and a beta of 1.26.

Extendicare Announces Dividend

The firm also recently announced a jul 25 dividend, which will be paid on Friday, August 15th. Investors of record on Thursday, July 31st will be given a $0.042 dividend. This represents a yield of 381.0%. The ex-dividend date is Thursday, July 31st. Extendicare's dividend payout ratio (DPR) is currently 61.20%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Stories

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Follow the Money: 5 Stocks Institutions Are Buying NOW
Strong Earnings? Market Says NVIDIA-Level Growth or Be Forgotten
Palantir’s Soaring Valuation—Justified or Overhyped?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines